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Purpose of the study
We report the case of a patient who presented with HIV
and MDR-TB who died unexpectedly of presumed car-
diac arrhythmia.
Methods
A 25 year old Lithuanian man was admitted with symp-
toms consistent with TB. He had cavitation on CXR
consistent with TB. He was HIV+ve with a CD4 count
of 16. His CMV titre was low positive. Standard TB
treatment was commenced on day 4. He started efavir-
enz and Truvada on day 12. On Day 18, his TB proved
to be multi-drug resistant; his anti-tuberculous therapy
was changed to IV amikacin, moxifloxacin, prothiona-
mide, ethambutol, and pyrazinamide. Cycloserine and
linezolid were added on day 21. Efavirenz was changed
to darunavir/boosted ritonavir due to psychiatric side
effects at day 28, and clofazamine and valganciclovir
were added on day 35. Fluconazole was added due to
oral candidiasis at day 45. Clinically, he improved over
the subsequent few days, and his CD 4 was 121 by day
41.
He was found dead unexpectedly on the ward on day
52, and the presumed cause of death was cardiac
arrhythmia. He was on low molecular weight heparin
and had been well during the week prior to his death.
There was no clinical suspicion of cardiac disease.
Observations were stable the day of his death and on
day 50 he had Hb 80g/dl WCC 1.51(neuts 0.78) CRP 78
and K+3.2 which were improved or similar to baseline.
No post mortem was performed.
Results
HIV is associated with cardiovascular complications,
including ischaemic heart disease, cardiomyopathy and
sudden death due to arrhythmia. It is also associated
with high early mortality in MDR-TB. He was on moxi-
floxacin, ondansetron, ritonavir and fluconazole which
are all known to prolong the QT interval. We suspect
he had a fatal arrhythmia due to his medication, plus or
minus HIV infection in combination with MDR-TB.
Immune reconstitution is postulated to cause sudden
death, but there was no evidence of cytokine storm in
this case.
Conclusion
We now plan to perform regular ECGs on patients on
long-term moxifoxacin and exercise caution in using
multiple agents which prolong the QT interval.
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